NCT07117487View on ClinicalTrials.gov

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2026

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

mRNA-1345

Suspension for injection

Trial Locations (11)

20854

NOT_YET_RECRUITING

Velocity Clinical Research, Rockville, Rockville

23666

NOT_YET_RECRUITING

Velocity Clinical Research, Hampton, Hampton

31406

NOT_YET_RECRUITING

Velocity Clinical Research, Savannah, Savannah

33012

RECRUITING

Indago Research & Health Center, Inc., Hialeah

46383

NOT_YET_RECRUITING

Velocity Clinical Research, Valparaiso, Valparaiso

68510

NOT_YET_RECRUITING

Velocity Clinical Research, Lincoln, Lincoln

70433

NOT_YET_RECRUITING

Velocity Clinical Research, Covington, Covington

78759

NOT_YET_RECRUITING

Velocity Clinical Research, Austin, Austin

80110

NOT_YET_RECRUITING

Velocity Clinical Research, Denver, Denver

97504

NOT_YET_RECRUITING

Velocity Clinical Research, Medford, Medford

99218

NOT_YET_RECRUITING

Velocity Clinical Research, Spokane, Spokane

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY